Isepamicin alone as antimicrobial prophylaxis for transrectal prostate needle biopsy: "Do we still need levofloxacin?
Hiroki Yamada1, Kojiro Tashiro1, Yusuke Takahashi1
1Department of Urology, The Jikei University Katsushika Medical Center, 6-41-2 Aoto, Katsushika-ku, Tokyo, 125-8506, Japan.
Abstract:
The purpose of this study was to investigate whether conventional levofloxacin (LVFX) administration is unnecessary for transrectal ultrasound-guided prostate needle biopsy (TRP-Bx) in view of the increase in LVFX-resistant Escherichia coli and appropriate use of antibiotics. The study included 636 cases undergoing TRP-Bx, divided into two groups based on the prophylactic antibiotic regimen. Group 1 (n = 308) received both oral levofloxacin (LVFX) 500 mg and intravenous isepamicin (ISP) 400 mg. Group 2 (n = 328) received only intravenous ISP 400 mg. Biopsies involved sampling 12 cores using an 18G needle. A high-risk subgroup included patients with a large prostate (>75 ml), severe dysuria, diabetes mellitus, or steroid use. Significantly more high-risk cases were in Group 2 than in Group 1 (35.7 % vs. 24.4 %, p = 0.003). Febrile genitourinary tract infections (fGUTIs) occurred in three patients (0.5 %), with no significant difference between the groups (0.3 % in Group 1 vs. 0.6 % in Group 2). No fGUTI complications were noted among high-risk cases in either group. Of the fGUTI cases, one involved LVFX-resistant E. coli; another involved E. coli susceptible to both LVFX and amikacin, isolated from blood. The single- and short-duration intravenous dose of ISP 400 mg would appear to be one of possible options in preventing TRP-Bx-related fGUTIs in both low-risk and high-risk patients.
Insights
Conventional levofloxacin (LVFX) may be unnecessary for prostate biopsies. A study found intravenous isepamicin alone effectively prevented infections, even in high-risk patients, suggesting optimized antibiotic use.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Background:
- Increasing levofloxacin (LVFX)-resistant Escherichia coli necessitates evaluating antibiotic prophylaxis for transrectal ultrasound-guided prostate needle biopsy (TRP-Bx).
- Optimizing antibiotic use is crucial to combat resistance and improve patient outcomes.
Purpose of the Study:
- To determine if conventional prophylactic levofloxacin (LVFX) is required for transrectal ultrasound-guided prostate needle biopsy (TRP-Bx).
- To assess the efficacy of intravenous isepamicin (ISP) alone versus combined LVFX and ISP for preventing TRP-Bx-related infections.
Main Methods:
- A comparative study of 636 patients undergoing TRP-Bx, divided into two groups: Group 1 (oral LVFX + IV ISP) and Group 2 (IV ISP only).
- Inclusion of a high-risk subgroup with factors like large prostate, dysuria, diabetes, or steroid use.
- Monitoring for febrile genitourinary tract infections (fGUTIs) post-biopsy.
Main Results:
- No significant difference in fGUTI rates between the two groups (0.3% vs. 0.6%).
- Febrile genitourinary tract infections (fGUTIs) occurred in only 0.5% of all patients.
- Intravenous isepamicin (ISP) alone was effective in preventing fGUTIs in both low- and high-risk patients.
Conclusions:
- Single-dose intravenous isepamicin (ISP) 400 mg appears sufficient for preventing TRP-Bx-related fGUTIs.
- Conventional levofloxacin (LVFX) prophylaxis may be unnecessary, supporting more judicious antibiotic use in prostate biopsy procedures.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Urine Studies II: Urine Culture and Sensitivity Test
Inhibitors of Bacterial DNA Synthesis


